Barrett’s Esophagus Diagnosis & Surveillance in Dallas, TX

What Is Barrett’s Esophagus?

Barrett’s esophagus is a condition in which the normal lining of the lower esophagus undergoes a transformation from its usual squamous cell tissue (flat, tile-like cells) to a specialized columnar epithelium with intestinal-type features — a process called intestinal metaplasia. This cellular change is an adaptive response to chronic acid exposure from gastroesophageal reflux disease (GERD). Over time, the persistent exposure to stomach acid and bile damages the esophageal lining, and the body replaces the injured cells with tissue that is more resistant to acid, but that also carries an increased risk of becoming cancerous.

Barrett’s esophagus is clinically significant because it is a precancerous condition — the only known precursor to esophageal adenocarcinoma, a type of esophageal cancer whose incidence has increased more than 600 percent in the United States over the past four decades. While the annual risk of any individual patient with Barrett’s esophagus developing cancer is relatively low (approximately 0.5 percent per year), the condition warrants ongoing surveillance to detect early changes (dysplasia) that may progress toward cancer.

Barrett’s esophagus affects approximately 5 to 10 percent of patients with chronic GERD symptoms, though many cases remain undiagnosed because the condition itself produces no unique symptoms. Population-based studies estimate that Barrett’s esophagus affects 1.6 to 6.8 percent of the general adult population.

At Texas Gut Health in Sachse, TX, Dr. Jaison John provides expert diagnosis, surveillance, and management of Barrett’s esophagus for patients throughout the Dallas-Fort Worth area. Dr. John completed his gastroenterology fellowship at UT Medical Branch, where he served as Chief Fellow, and his internal medicine residency at UT Austin Dell Medical School, where he served as Chief Resident. He holds dual board certifications from the American Board of Internal Medicine in both internal medicine and gastroenterology.

The Connection to GERD

GERD is the primary risk factor for Barrett’s esophagus. Chronic exposure of the esophageal lining to stomach acid and bile causes repeated cycles of injury and healing that, over time, can trigger the metaplastic change characteristic of Barrett’s esophagus. Key points about the GERD-Barrett’s relationship include:

• Duration of GERD symptoms matters — The risk of Barrett’s esophagus increases with the duration and frequency of GERD symptoms. Patients with GERD symptoms lasting more than 5 to 10 years are at significantly higher risk than those with short-duration symptoms.
• Frequency and severity of reflux — More frequent and more severe reflux episodes increase the risk. Nocturnal reflux (reflux that occurs during sleep) is particularly associated with Barrett’s esophagus because lying flat allows more prolonged acid contact with the esophageal lining.
• Not all GERD patients develop Barrett’s — Only approximately 5 to 10 percent of patients with chronic GERD develop Barrett’s esophagus, suggesting that genetic susceptibility and other factors play a role in determining who is affected.
• Absent symptoms do not exclude Barrett’s — Some patients with Barrett’s esophagus report a paradoxical improvement or absence of heartburn symptoms. This may occur because the metaplastic tissue is less acid-sensitive than normal esophageal tissue, giving a false sense of improvement.

Risk Factors

Several factors increase the likelihood of developing Barrett’s esophagus. The American College of Gastroenterology (ACG) recommends screening for Barrett’s esophagus in patients with chronic GERD symptoms who have three or more of the following risk factors:

• Male sex — Barrett’s esophagus is approximately twice as common in men as in women. Esophageal adenocarcinoma is 3 to 4 times more common in men.
• Age over 50 — The average age at diagnosis of Barrett’s esophagus is approximately 55 years, though it can occur at younger ages.
• Caucasian race — Barrett’s esophagus and esophageal adenocarcinoma are significantly more common in Caucasians than in other racial groups.
• Central (abdominal) obesity — Excess abdominal fat increases intra-abdominal pressure, worsens GERD, and is independently associated with Barrett’s esophagus and esophageal adenocarcinoma through metabolic and inflammatory pathways.
• Cigarette smoking — Current or past smoking increases the risk of Barrett’s esophagus. Smoking cessation reduces but does not entirely eliminate this risk.
• Family history — Having a first-degree relative with Barrett’s esophagus or esophageal adenocarcinoma increases the risk. A familial predisposition is recognized in approximately 7 to 10 percent of cases.

Conversely, Helicobacter pylori infection (particularly with CagA-positive strains) appears to be inversely associated with Barrett’s esophagus and esophageal adenocarcinoma, possibly because it reduces gastric acid secretion over time.

Diagnosis

Barrett’s esophagus is diagnosed through an upper endoscopy (EGD) with biopsies. The diagnosis requires both endoscopic visualization of columnar-appearing tissue in the esophagus and histologic (microscopic) confirmation of intestinal metaplasia on biopsy.

Endoscopic Findings

During upper endoscopy, Barrett’s esophagus appears as salmon-colored or reddish tissue extending upward from the gastroesophageal junction (GEJ) into the lower esophagus, in contrast to the normal pale, pinkish-white squamous lining of the esophagus. The extent of Barrett’s tissue is described using the Prague C and M classification, which measures the circumferential (C) and maximum (M) length of the Barrett’s segment in centimeters. Barrett’s esophagus is classified as:

• Short-segment Barrett’s esophagus — Barrett’s tissue extending less than 3 centimeters above the GEJ.
• Long-segment Barrett’s esophagus — Barrett’s tissue extending 3 centimeters or more above the GEJ. Long-segment Barrett’s carries a higher cancer risk than short-segment disease.

Biopsy Protocol

The ACG recommends obtaining biopsies using the Seattle protocol: systematic four-quadrant biopsies taken at every 1 to 2 centimeter interval along the entire length of the Barrett’s segment, plus targeted biopsies of any visible mucosal irregularities (nodules, ulcers, or areas of abnormal appearance). This thorough approach maximizes the likelihood of detecting dysplasia, which can be patchy and invisible to the naked eye.

Dysplasia and Cancer Risk

Dysplasia — the presence of abnormal, precancerous cellular changes — is the most important factor in determining Barrett’s esophagus prognosis and guiding management decisions. Dysplasia is classified into the following categories:

No Dysplasia

The majority of patients with Barrett’s esophagus (approximately 90 percent) have no dysplasia at the time of diagnosis. The annual risk of progression to esophageal adenocarcinoma in patients without dysplasia is approximately 0.5 percent per year (roughly 1 in 200 patients per year). These patients require surveillance endoscopy but not endoscopic treatment of the Barrett’s tissue itself.

Indefinite for Dysplasia

In some cases, the pathologist identifies cellular changes that are suspicious but not definitively diagnostic of dysplasia, often due to the presence of inflammation. These patients should be treated with aggressive acid suppression (high-dose PPI therapy) for 3 to 6 months, followed by repeat endoscopy and biopsy to reassess.

Low-Grade Dysplasia (LGD)

Low-grade dysplasia indicates early precancerous changes in the Barrett’s tissue. The risk of progression to cancer is estimated at 0.7 to 1 percent per year, though some studies suggest it may be higher. The ACG recommends that the diagnosis of LGD be confirmed by an expert gastrointestinal pathologist, as there is significant inter-observer variability in dysplasia grading. For confirmed LGD, the ACG recommends either endoscopic eradication therapy or surveillance endoscopy every 6 to 12 months.

High-Grade Dysplasia (HGD)

High-grade dysplasia represents advanced precancerous changes that are one step short of invasive cancer. The annual risk of progression to esophageal adenocarcinoma is approximately 6 to 19 percent, and some patients with HGD may already have occult cancer in the resected specimen. The ACG strongly recommends endoscopic eradication therapy for confirmed high-grade dysplasia, as it has been shown to dramatically reduce cancer progression.

Surveillance Endoscopy Protocols

Regular surveillance endoscopy is a cornerstone of Barrett’s esophagus management. The purpose of surveillance is to detect dysplasia at an early stage when it can be treated endoscopically, before it progresses to invasive esophageal adenocarcinoma. The ACG recommends the following surveillance intervals:

• Barrett’s esophagus without dysplasia — Surveillance upper endoscopy with systematic biopsies every 3 to 5 years.
• Low-grade dysplasia (if not treated) — Surveillance endoscopy every 6 to 12 months.
• High-grade dysplasia — Endoscopic eradication therapy is recommended rather than continued surveillance alone.

During each surveillance endoscopy, the Seattle protocol is followed for biopsy sampling, and any visible mucosal abnormalities are biopsied separately. High-definition endoscopy and advanced imaging techniques (such as narrow-band imaging or chromoendoscopy) are used to enhance visualization of subtle mucosal changes that might harbor dysplasia.

It is important for patients to understand that surveillance is a long-term commitment. While the annual risk of cancer in non-dysplastic Barrett’s is low, the cumulative risk over a lifetime of living with Barrett’s esophagus makes regular follow-up essential. Patients who discontinue surveillance face the risk of having cancer detected at a more advanced and less treatable stage.

Treatment

Treatment of Barrett’s esophagus depends on whether dysplasia is present and its grade.

Medical Management (All Barrett’s Patients)

All patients with Barrett’s esophagus should receive treatment for the underlying GERD to minimize ongoing acid exposure to the esophageal lining:

• Proton pump inhibitor (PPI) therapy — The ACG recommends once-daily PPI therapy for all patients with Barrett’s esophagus, regardless of whether they have GERD symptoms. PPIs reduce acid production and may slow the progression of Barrett’s esophagus, though they do not reverse the metaplastic change. Some patients with ongoing symptoms or large hiatal hernias may benefit from twice-daily PPI therapy.
• Lifestyle modifications — Weight loss (if overweight), elevation of the head of the bed, avoiding meals within 2 to 3 hours of bedtime, and avoiding known GERD triggers (fatty foods, caffeine, alcohol, chocolate, citrus, tomatoes) can help reduce reflux symptoms and acid exposure.

Endoscopic Eradication Therapy

For Barrett’s esophagus with confirmed dysplasia, endoscopic eradication therapy (EET) is the standard of care. EET aims to eliminate the dysplastic and metaplastic tissue using techniques performed through the endoscope, avoiding the need for major surgery. The two primary modalities are:

• Radiofrequency ablation (RFA) — RFA uses controlled radiofrequency energy delivered through a specialized catheter to heat and destroy the Barrett’s tissue. The destroyed tissue is replaced by normal squamous epithelium as it heals. RFA is typically performed in multiple sessions spaced 2 to 3 months apart until complete eradication of the Barrett’s tissue is achieved. Large clinical trials, including the landmark AIM dysplasia trial, demonstrated that RFA eliminates dysplasia in approximately 90 percent of patients and achieves complete eradication of intestinal metaplasia in 77 to 98 percent. RFA significantly reduces the risk of progression to esophageal adenocarcinoma.
• Endoscopic mucosal resection (EMR) — EMR involves the physical removal of visible nodules, bumps, or raised areas of Barrett’s tissue using techniques performed through the endoscope. It serves two purposes: therapeutic removal of abnormal tissue and provision of a tissue specimen for detailed histologic analysis. EMR is often used in combination with RFA — EMR first addresses any visible lesions, and RFA then treats the remaining flat Barrett’s tissue.

Other ablative techniques include cryotherapy (freezing), which may be used for residual Barrett’s tissue after initial RFA treatment or in patients who are not candidates for RFA.

Esophageal Dilation

Some patients with Barrett’s esophagus develop esophageal strictures (narrowing) from chronic inflammation, scarring, or as a complication of ablative therapy. Esophageal dilation can be performed during endoscopy to gently stretch the narrowed area and relieve difficulty swallowing (dysphagia).

Post-Eradication Surveillance

Even after successful endoscopic eradication of Barrett’s esophagus, the condition can recur. Studies show a recurrence rate of approximately 20 to 30 percent over 5 to 10 years. For this reason, the ACG recommends ongoing surveillance endoscopy after successful eradication:

• Every 3 months for the first year after eradication of high-grade dysplasia
• Every 6 months in the second year
• Annually thereafter

Patients must also remain on PPI therapy indefinitely after eradication to maintain acid suppression and reduce the risk of recurrence.

Esophageal Adenocarcinoma: Understanding the Risk

Barrett’s esophagus is the only known precursor to esophageal adenocarcinoma, which is one of the fastest-growing cancers in the Western world. Key facts for patients to understand include:

• The absolute risk is low but real — The annual risk of developing esophageal adenocarcinoma from Barrett’s esophagus without dysplasia is approximately 0.5 percent per year. While this means the vast majority of Barrett’s patients will never develop cancer, the risk is elevated compared to the general population and warrants surveillance.
• Dysplasia is the warning sign — The progression from Barrett’s to cancer typically follows a stepwise pathway: intestinal metaplasia, low-grade dysplasia, high-grade dysplasia, and then invasive adenocarcinoma. Detecting and treating dysplasia is the key to cancer prevention in Barrett’s patients.
• Early detection saves lives — When esophageal adenocarcinoma is detected at an early stage (confined to the superficial layers of the esophageal wall), it can often be treated endoscopically with excellent outcomes. When detected at an advanced stage, the prognosis is significantly worse, with a 5-year survival rate of less than 20 percent.
• Surveillance works — Studies have consistently shown that patients whose esophageal adenocarcinoma is detected through Barrett’s surveillance programs have earlier-stage disease and better survival outcomes than those whose cancer is detected outside of a surveillance program.

It is important for patients to understand that while Barrett’s esophagus requires ongoing attention and monitoring, the overall risk of cancer is manageable with appropriate surveillance and treatment of dysplasia. The goal of Barrett’s management is to detect and treat precancerous changes early, preventing cancer from developing in the first place.

Frequently Asked Questions